Cryptotanshinone inhibits IgE-mediated degranulation through inhibition of spleen tyrosine kinase and tyrosine-protein kinase phosphorylation in mast cells

SUMIYASUREN BUYANRAVIKH*†, SORA HAN*, SUNYI LEE, AE LEE JEONG, HYE IN KA, JI YOUNG PARK, ARIUUNDA V BOLDBAATAR, JONG-SEOK LIM, MYEONG-SOK LEE and YOUNG YANG

Department of Biological Science, Sookmyung Women's University, Seoul 04310, Republic of Korea

Received December 15, 2017; Accepted May 4, 2018

DOI: 10.3892/mmr.2018.9042

Abstract. Atopic dermatitis (AD) is a type of chronic skin inflammation and one of the most common relapsing allergic diseases, which presents with a severe rash and itchy skin lesions. The pathogenesis of AD is primarily associated with hyper-activated mast cells, which makes them an effective treatment target. After cross-linking the antigen/immunoglobulin (Ig) E complex binds to its high affinity receptor FcεRI on the surface of mast cells. The cells subsequently secrete excessive pro-inflammatory mediators, including histamine and cytokines, which lead to pruritus and immune cell infiltration in the skin lesions. The present study screened natural compounds that have an inhibitory effect on IgE/antigen-mediated secretory activity. It was revealed that cryptotanshinone (CRT), a natural compound extracted from Salvia miltiorrhiza Bunge, had inhibitory effects on the IgE/antigen complex. The underlying mechanism by which CRT exerted an anti-allergy/inflammatory function was investigated using rat basophilic leukaemia (RBL) cells for degranulation assays and a 1-chloro-2,4-dinitrobenzene (DNCB)-induced AD Balb/c mouse model for in vivo study. CRT effectively mitigated the secretion of pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin 1β, as well as immune cell infiltration into skin lesions in a mouse model of AD-like skin disease induced by dinitrochlorobenzene. The inhibitory effect of CRT on IgE-mediated mast cell degranulation was mediated by the inhibition of tyrosine kinase-dependent degranulation signalling pathways involving spleen tyrosine kinase and Lyn. The present study revealed CRT as an inhibitor of mast cell degranulation. Therefore, CRT may be considered for development as a therapeutic drug to treat IgE-mediated skin diseases.

Introduction

Atopic dermatitis (AD) is a chronic skin inflammation and one of the most common relapsing allergic diseases. The incidence of AD has gradually been increasing worldwide. The etiology of the disease is associated with innate and adaptive immune responses, which are caused by environmental and genetic factors; AD mostly occurs in infants and children (1). The clinical characteristics of AD are prevalently related to an excessive accumulation of antigen and imbalance of allergen-specific T helper (Th1/Th2) cells and inflammatory cytokines. Those inflammatory cytokines contribute to increase levels of immunoglobulin (Ig) E and produce other pro-inflammatory mediators to trigger infiltration of inflammatory immune cells, such as granulocytes, lymphocytes, macrophages, eosinophils, and mast cells into skin lesions (2). The repeated exposure of antigen produces more severe and chronic AD symptoms, including skin barrier disruption, pruritus, excoriation, and dryness. In most cases, patients with AD are treated with synthetic steroids. However, many clinical reports have warned that long-term use of synthetic steroids may result in side effects such as additional infections, gastrointestinal ulcers, osteoporosis, and insomnia (3-5). Therefore, the identification of novel anti-allergic naturally-derived agents from herbs and medicinal plants with less side effects are required for AD treatment.

Mast cells play an important role in type I hypersensitivity reactions via the release of histamine, chemokines, and various inflammatory cytokines. Secretion and activation of these strong pro-inflammatory mediators are stimulated by binding of the cross-linked IgE/antigen complex and its high affinity receptor FcεRI on surfaces of mast cells (6). Previous studies have revealed that IgE/antigen-FceRI binding activates IκB kinase α and β (IKKα and IKKβ), leading to the activation of nuclear factor-κB (NF-κB), which translocates into nucleus to regulate the inflammatory response. Conversely, IgE/antigen-FceRI binding phosphorylates synaptosome-associated protein 23 (SNAP-23)

Correspondence to: Professor Young Yang, Department of Biological Science, Sookmyung Women’s University, Cheongpa-ro 47-gil-100, Yongsan-gu, Seoul 04310, Republic of Korea

E-mail: yyang@sookmyung.ac.kr

*Contributed equally

Key words: atopic dermatitis, cryptotanshinone, 1-chloro-2,4-dinitrobenzene, Balb/c, degranulation, RBL-2H3
in an NF-κB-independent manner, which is responsible for late-phase allergic reactions (7,8). Finally, activated NF-κB increases the production and secretion of pro-inflammatory cytokines including tumor necrosis factor α (TNF-α), interleukin (IL)-1β, -4, and -6 (9,10). Accordingly, it is considered that both the inhibition of pro-inflammatory cytokine production and of NF-κB dependent signalling pathways are effective strategies to ameliorate allergic reactions.

Previous studies have revealed that tanshionones, including tanshinone-I, tanshinone-IIA, and 15,16-dihydrotanshinone-I, reduce allergic reactions in rat mast cells RBL-2H3 via suppressing their degranulation. More specifically, 15,16-dihydrotanshinone-I inhibits the activation of extracellular signal-regulated kinases 1/2 (ERK1/2), spleen tyrosine kinase (Syk), and phospholipase Cγ2 (PLCγ2) which are signalling molecules that induce mast cell degranulation (11). Furthermore, components of **Salvia miltiorrhiza Bunge** have anti-allergic, anti-inflammatory, and anticancer activities (12,13) and are used to treat cardiovascular disorders (14,15) Cryptotanshinone (CRT), one of the major natural compounds extracted from the medicinal herb *Salvia miltiorrhiza Bunge*, also belongs to the tanshinone group. In addition, CRT is known as an inhibitor of signal transducer and activator of transcription 3 (STAT3). Because STAT3 is a transcription factor that increases the transcription of pro-inflammatory cytokines, CRT is also able to inhibit the production of these cytokines. Specifically, CRT strongly inhibits phosphorylation at the Tyr705 residue at STAT3 with a small effect at the Ser727 residue, but has no activity against STAT1 or STAT5 (16). To date, little has been reported regarding the precise molecular target by which CRT inhibits mast cell degranulation.

**Materials and methods**

**Reagents.** CRT, Dulbecco's modified Eagle's medium (DMEM), foetal bovine serum (FBS), phosphate-buffered saline (PBS), dinitrophenyl-bovine serum albumin (DNP-BSA), anti-dinitrophenyl IgE isotype (DNP-IgE), 4-nitrophenyl-N-acetyl-D-glucosamine, citrate buffer, sodium bicarbonate, 1-chloro-2,4-dinitrobenzene (DNCB), lipopolysaccharide (LPS), and 10% neutral-buffered formalin were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Dimethyl sulfoxide (DMSO) was purchased from Takara Bio Inc. (Shiga, Japan). Dexemethasone and primary antibody against β-actin were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). Primary antibodies against phospho-IκBα, IκBα, phospho-NF-κB p65, NF-κB p65, phospho-Lyn, Lyn, phospho-Syk, Syk, phospho-PLCγ1, PLCγ1, phospho-protein kinase C (PKC), PKC, phospho-ERK1/2, and ERK1/2 were purchased from Cell Signaling Technology, Inc., Danvers, MA, USA.

**Cell culture.** The rat basophilic leukaemia (RBL) cell line RBL-2H3 was a kind gift from professor Jean-Pierre Kinet (Harvard University, Cambridge, MA, USA). The RBL-2H3 cell line shares characteristics with human mucosal mast cells (17-19), which makes it an appropriate cell line to use within the present study. RBL-2H3 cells were cultured in DMEM supplemented with 10% FBS at 37°C in an incubator under 5% CO₂ conditions.

**Mast cell degranulation assay.** RBL-2H3 cells were plated in 6-well plate (2x10⁴ cells/well) or 96-well plate (5x10⁴ cells/well) and were sensitized with anti-DNP-IgE (0.1 µg/ml) for 16 h. After washing two times with PBS, the cells were pre-treated with CRT at indicated concentrations for indicated times then sensitized with DNP-BSA (100 ng/ml) for an additional 1 h. For the measurement of β-hexosaminidase release (a biomarker of degranulation) from RBL-2H3 cells, 50 µl of cell supernatant was incubated with a same volume of solution I [substrate solution: 1.3 mg/ml of 4-nitrophenyl-N-acetyl-D-glucosamine in 0.1 M sodium carbonate] at 37°C for 1 h and the reaction was terminated by adding stop solution II [50 mM sodium carbonate] for 15 min at room temperature. The measurement of β-hexosaminidase release was determined using a microplate reader at an absorbance of 405 nm (Molecular Devices, LLC, Sunnyvale, CA, USA).

**Luciferase assay.** 293T cells were transfected with 200 ng of pGL3-3×NF-κB luciferase reporter plasmid using polyethylenimine solution (Sigma-Aldrich; Merck KGaA), then incubated overnight. pEGFP plasmid was used as control. 5, 10, 20 µM CRT was pre-treated to transfected cells for 1 h. Then, cells were stimulated with LPS. After 1 h of incubation, the cells were lysed and luciferase activity was determined using Luciferase Reporter Assay System (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions.

**Animals.** Male 6-week old Balb/c mice (20-25 g; Koatech, Gwangju-do, Korea) were housed under 12-h light/12-h dark conditions and were allowed free access to food and water. The bedding was changed once a week, and the temperature (22-23°C) and humidity (40-55%) were controlled. All procedures were conducted at the animal facilities and this animal experiments were approved by the Institutional Animal Care and Use Committee of Sookmyung Women's University, Seoul, Korea (SMWU-IACUC-1611-035).

**DNBC-induced AD animal model.** Balb/c mice were randomly divided into three groups (n=5 per group). The day after shaving the dorsal skin of all mice, the control, and experimental groups were sensitized by the application of DNCB solution by painting (dissolved in a 3:1 mixture of acetone and olive oil). After 5 days, 20 µl of 0.2% DNCB solution was applied on both the left and right ears, and 100 µl was applied on the shaved dorsal skin every other day; the vehicle group received applications of DMSO only. In the experimental group, the same volume of 100 µM CRT was applied by painting on both ears and on the dorsal skin 1 h before every DNCB challenge. The thickness of right and left ears of all mice were measured every other day with a dial caliper (Ozaki Factory, Tokyo, Japan). All mice were sacrificed on day 31 of the experiment by CO₂ euthanasia and tissues were collected.

**Histological analysis.** The inflamed ear specimens of each mouse were collected and fixed with 10% neutral-buffered formalin. All fixed tissues were embedded using a frozen section compound and were cut into 20 µm-thick sections using a rotary microtome (both Leica Microsystems, Inc., Buffalo Grove, IL, USA). To compare the swelling of the epidermis and inflammatory cell accumulation, each
section was stained with haematoxylin and eosin (H&E; Sigma-Aldrich; Merck KGaA). For immunofluorescence, tissues were treated with PBS-based 0.1% Triton-X-100 for 10 min to permeabilize the tissue. After washing with PBS, slides were blocked by PBS-based 1% BSA for 30 min at room temperature. Then slides were incubated with phycoerythrin (PE) conjugated-anti-mouse cluster of differentiation molecule 11b (CD11b; CA, USA), a marker of inflammatory granulocytes for 1 h at room temperature in the dark. After washing with PBS twice, slides were cover-slipped. Confocal images were obtained with a Zeiss confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).

Measurement of IgE levels by enzyme linked immunosorbent assay (ELISA). Blood was collected by cardiac puncture from isoflurane-anesthetized mice on the last day of experiments. Clotted blood samples were centrifuged (3,500 rpm for 20 min) and serum was collected. Ear tissues from mice were homogenized with RIPA buffer [20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1% SDS, Complete Protease Inhibitor Cocktail Tablets (Roche, Basel, Switzerland)] and centrifuged at 12,000 g for 15 min to obtain tissue lysates. The level of IgE from mouse serum and tissue lysates were determined by a commercial mouse IgE ELISA assay kit (Shibayagi, Shikubawa, Japan) according to the manufacturer's instructions.

Quantitative RT-PCR (qRT-PCR) Frozen tissue from mice or RBL-2H3 cells were lysed with RNAiso plus reagent (Takara Bio Inc.) and total RNA was extracted according to the manufacturer's instructions. The isolated total RNA was reverse transcribed (RT) using M-MuLV RTase (Promega Corp.) at 42˚C for 1 h. qRT-PCR was performed using SYBR®-Green master mix (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and Applied Biosystems QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Inc.). 18s rRNA was used as loading control. Fold changes of indicated target gene-ΔΔCt method, where ΔΔCt=(Ct target gene-ΔCt 18S rRNA) Control group. The following primer sets were used: IL-1β forward, 5’-AGCCCATCTGTCGACTCATG-3’ and reverse, 5’-GCTGATGTACACCAGTTGGGGAAC-3’; IL-6 forward, 5’-CCGGAGAGGAGACTTCAGAG-3’ and reverse, 5’-TCAACATTTCCGAGAAGC-3’; TNF-α forward, 5’-CCTGTAGCCACGGCTAGACG-3’ and reverse, 5’-TTGACCTCAGGCGTACTGGTGTT-3’; monocyte chemoattractant protein 1 (MCP-1) forward, 5’-ATCCCAATGAGTGCGCTGAGA-3’ and reverse, 5’-CAGAAGTGTCTTGAGGTTGGT-3’; 18s rRNA forward, 5’-AGCTATCAATTCTTGTCATACCTCGTGC-3’ and reverse, 5’-GCTTAAAATTCACTCAACACGGGA-3’.

Western blot analysis. Cells and tissue from mice were lysed with GST-IP buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, Complete Protease Inhibitor Cocktail Tablets (Roche)] or RIPA buffer, respectively. For analysing phosphorylated proteins, PhosSTOP EASYpack (Roche) was added to the lysis buffer. Protein lysates were obtained by further centrifuge (13,000 rpm for 15 min). Then, obtained lysates were mixed with 5x sodium dodecyl sulphate (SDS) sample buffer and heated at 95˚C for 5 min. Prepared sample were separated by 12% SDS-Polyacrylamide gel and transferred to a nitrocellulose membrane (GE Healthcare, Little Chalfont, UK). After blocking with TBST-based 3% BSA for 30 min at room temperature, the membranes were incubated with indicated primary antibodies at 4˚C overnight. Then, membranes were further incubated with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (Fab) secondary antibodies (Enzo Life Sciences Inc., Farmingdale, NY, USA) for 2 h at room temperature. The target proteins were analysed by PowerOpti-ECL western blotting reagent (Thermo Fisher Scientific, Inc.) and evaluated using a luminescent image analyser Fusion Solo (Vilber Lourmat, Eberhardzell, Germany). The size of protein in each blot was expected by relative migration ratio to prestained protein size marker (Thermo Fisher Scientific, Inc.) and β-actin in each blot was detected to normalize protein amount. Images were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Results

CORT suppressed IgE-mediated mast cell degranulation. In order to identify effective candidates having anti-allergic activity, we screened 133 natural compounds with an IgE-mediated degranulation assay using RBL cell line RBL-2H3, which is widely accepted and applied as a proper model for human mucosal mast cells. Compared to other compounds, CORT showed the greatest anti-allergy effects as it significantly decreased IgE/DNP crosslink-mediated degranulation in RBL-2H3 cells (Fig. 1A). Furthermore, CORT suppressed IgE/DNP-mediated mast cell degranulation dose-dependently and its effects at the maximum dose was similar to that of dexamethasone at 10 µg/ml (Fig. 1B). No cytotoxic effects of CORT were observed (Fig. 1C), indicating that the suppressive effect of CORT on mast cell degranulation was not due to cytotoxicity.

CORT alleviated DNBC-induced AD symptoms in the mouse model. To determine whether CORT has curable effects on AD-like skin lesions, a DNBC-induced AD animal model was generated using Balb/c mice and was then subjected to CORT treatment as shown in the experimental design (Fig. 2). The repeated DNBC challenge successfully induced AD-like symptoms, as mice showed markedly increased ear swelling as compared to the vehicle group. When CORT was pre-treated 1 h before every DNBC challenge, ear swelling was significantly reduced after 2 weeks of CORT treatment (Fig. 3A and B). Histological analyses also confirmed that CORT treatment attenuated AD-like inflammation and skin tissue damage.
induced by DNCB (Fig. 3C). Next, immunofluorescence analysis was performed to investigate whether the effects of mitigation of ear swelling induced by CRT could be associated with a reduction in immune cell recruitment to the inflammatory skin lesion. Interestingly, CRT treatment also restored DNCB-induced excessive accumulation of CD11b-positive immune cells in the ear skin lesion (Fig. 3D), indicating that CRT alleviates DNCB-induced AD-like skin symptoms. In addition, CRT greatly suppressed increased spleen weights by DNCB (Fig. 3E). Given that the spleen weight is an
indicator evaluating the degree of inflammation, those observations suggest that CRT exerts the anti-AD effect through its anti-inflammatory effect.

**CRT decreased transcription levels of pro-inflammatory cytokines and inhibited the NF-κB signalling pathway in the AD-like skin lesion in the DNCB-induced animal model.** Since the allergen-specific IgE involves in the initial phase of the allergic response, the increased levels of allergen-specific IgE is a hallmark of AD. Thus, we isolated serum and ear tissue lysates and then measured IgE levels by ELISA. DNCB-challenged mice exhibited a significant increase in serum IgE levels, but no significant changes were observed with CRT treatment compared to DNCB-challenged mice (Fig. 4A). However, IgE levels in lysates from ear tissues were decreased by CRT treatment (Fig. 4B), implying that CRT decreases the local IgE level at nearby inflamed region.

Next, we evaluated whether the CRT has inhibitory effects on pro-inflammatory cytokines including IL-1β and TNF-α, which are known to be upregulated and play important roles associated with the NF-κB signalling pathway under inflammation-challenged conditions. Therefore, the transcription levels of pro-inflammatory cytokines in ear tissues were determined by qRT-PCR. As expected, CRT treatment significantly reduced DNCB-challenged upregulation of IL-1β (Fig. 4C) and TNF-α (Fig. 4D). Next, we examined the inhibitory effect of CRT on the activation of the NF-κB pathway in inflamed ear tissues isolated from a DNCB-induced AD animal model. CRT showed a suppressive effect on DNCB-induced NF-κB p65 phosphorylation (Fig. 4E).

**CRT inhibited the transcriptions of inflammatory cytokines by suppression of IgE-mediated ERK 1/2 and NF-κB activation in RBL-2H3 cells.** Cross-linking of the IgE/antigen complex stimulates mast cells to produce pro-inflammatory cytokines through activation of the MAPK ERK 1/2 and NF-κB signalling pathways. Thus, the effect of CRT on ERK 1/2 and NF-κB signalling pathway activation was examined using RBL-2H3 cells. IgE-cross-linking by DNP/BSA treatment activated ERK 1/2 by increasing phosphorylation, but pre-treatment with CRT dose-dependently suppressed ERK 1/2 activation in RBL-2H3 cells. Phosphorylation of NF-κB p65 and IκBα were increased by IgE cross-linking; however, CRT treatment inhibited their phosphorylations in a dose-dependent manner (Fig. 5A).

Next, we asked whether CRT directly regulates the activity of NF-κB. To address this, 293T cells were transfected with NF-κB luciferase reporter gene, because 293T cells show higher transient transfection efficiency than RBL-2H3 cells. The transfected cells were treated with LPS treatment to activate NF-κB. Following co-treatment with CRT and LPS, CRT significantly suppressed LPS-activated NF-κB luciferase activity (Fig. 5B). These results indicated that CRT significantly
mitigates the IgE-mediated NF-κB activation in RBL-2H3 cells. Moreover, CRT treatment also decreased the transcription levels of TNF-α and IL-6 increased by IgE cross-linking in RBL-2H3 cells (Fig. 5C). In addition to these inflammatory cytokines, the expression of MCP-1, a key chemokine involved in the stimulation of infiltration and migration of leukocytes towards the inflammatory lesion, was also examined. Interestingly, the IgE cross-linking-induced upregulation of MCP-1 was completely restored to normal levels by CRT treatment (Fig. 5C), suggesting that the decreased accumulation of CD11b positive cells in AD-like skin lesions from CRT-treated mice might be caused by a reduced expression of chemotactrant MCP-1.

**CRT inhibited IgE-mediated mast cell activation through suppression of Lyn/Syk phosphorylation and its downstream signalling pathway.** Next, to reveal exact molecular targets of CRT, we examined effect of CRT on phosphorylation of Lyn and Syk kinases, which are the most upstream kinases responsible for mast cell activation. CRT treatment suppressed phosphorylation levels of Lyn and Syk in activated RBL-2H3 cells (Fig. 6A). We also examined phosphorylation levels of PLCγ, PKCδ, and IKKβ, which are downstream target molecules of p-Lyn and p-Syk. CRT also greatly suppressed phosphorylation of PLCγ, PKC, and IKKβ in a dose-dependent manner (Fig. 6B). CRT effects on p-PLCγ, p-PKC, and p-IKKβ showed its best efficiency with 10 µM of concentration. These results suggest that CRT suppresses IgE-mediated mast cell degranulation by inhibiting the activation of Lyn and Syk kinases (Fig. 6C).

**Discussion**

Chronic AD patients have a higher risk of developing allergic rhinitis and asthma, which are triggered by pro-inflammatory mediators released from activated and infiltrated immune cells including mast cells, neutrophils, and macrophages into skin lesions (20,21). To prevent complications and relieve AD symptoms, powerful immunosuppressive steroids are used for treatment, but the beneficial effects are short-lived; thus, patients have to take these steroid drugs chronically. Furthermore, taking steroid drugs continuously for prolonged periods of time leads to severe side effects such as blood disorders, irregular heartbeat, and psychological interference (22). Accordingly,
identifying biologically active natural compounds from medicinal plants and developing alternative anti-AD drugs with fewer side effects are in demand to alleviate AD.

In this study, we evaluated the anti-AD effects of CRT using a DNCB-induced AD mouse model, which is typically used for studying the pathogenesis of AD (4). Topical application of CRT attenuated ear swelling induced by DNCB. In addition, the excessive accumulation of CD11b-positive immune cells in skin lesions triggered by repeated exposure to DNCB on Balb/c mice was dramatically decreased by CRT treatment. In addition, DNCB is known to significantly increase TNF-α and IL-1β levels in mice and these cytokines enhance the expression of adhesion molecules and increase vascular permeability and facilitating the recruitment of inflammatory cells to the skin lesion (23-26). In our study, CRT strongly suppressed mRNA levels of DNCB-induced TNF-α and IL-1β, likely resulting in the observed blocked recruitment of immune cells to the skin lesion. However, further studies are required to identify immune cell types decreased by CRT, because monocytes, neutrophils, basophils, mast cells, and eosinophils all express CD11b on their cell surfaces. Conversely, it has previously been reported that extracts from *Salvia miltiorrhiza Bunge* show immunomodulatory effects by increasing the population of host immune cells, including macrophages, natural killer (NK) cells, and peripheral lymphocytes, and by decrease in serum levels of IgE and the pro-inflammatory cytokine IL-1β against *Listeria monocytogenes* infection in Balb/c mice (27). Thus, CRT could be the major component in *Salvia miltiorrhiza Bunge* extracts which exerts the potent anti-AD effects.

We showed that CRT exerts anti-AD effect through inhibition of the mast cell degranulation in mast cells. Upon IgE/antigen stimulation, the immunoreceptor tyrosine-based activation motif (ITAM) region of FceRI receptor which is on the mast cell surface is phosphorylated and the initial signalling protein kinases Lyn and Syk are recruited to the ITAM. Then, Lyn and Syk are activated through autophosphorylation, which leads to phosphorylation of the transmembrane adaptor linker for activation of T cells (LAT). Phosphorylated LAT which is a scaffold for multimolecular signalling complexes and activates PLCγ through phosphorylation. The activated PLCγ hydrolyses phosphatidylinositol biphosphate (PIP2) to generate second signalling molecules IP3 and DAG, which activate PKCδ through phosphorylation. Then, activated PKCδ phosphorylates IKKβ so IKKβ moves to the plasma membrane, resulting in the induction of mast cell degranulation (6,11,28,29). In this study, novel function of CRT on phosphorylations of Lyn/Syk kinases in mast cells is elucidated for the first time. Furthermore, it is likely that this inhibitory effect of CRT on Lyn/Syk kinases negatively affected activities of their downstream signalling molecules including PLCγ, PKCδ, and IKKβ, which leads to decrease in mast cell degranulation by CRT treatment.

Besides the inhibitory effect of CRT on mast cell degranulation, here we provide additional evidence that CRT exerts anti-AD effects through inactivation of MAPK and NF-κB. It has been reported that CRT regulates the activities of MAPK and NF-κB in various cell types. In rhabdomyosarcoma, hepatoma, and breast carcinoma, CRT activates MAPK p38/JNK and suppresses ERK1/2, followed
by caspase-independent apoptosis (10,30,31). In chronic myeloid leukaemia cells, CRT enhances TNF-α-induced apoptosis through the activation of MAPK p38 (32). In smooth muscle cells, CRT exerts anti-migration/invasion effect as it inhibits TNF-α/NF-κB signalling pathway (33). In this study, we elucidated the anti-inflammatory role of CRT in mast cells as CRT suppresses the IgE/antigen-induced phosphorylation of ERK1/2 and IκBα/NF-κB. Furthermore, the luciferase assay revealed that CRT directly inhibits the LPS-induced NF-κB activity, suggesting that CRT decreases the transcriptions of pro-inflammatory cytokines by downregulation of NF-κB activity. Given that IκKβ regulates IκBα/NF-κB signalling pathway and that the activity of IκKβ is controlled by the Lyn/Syk signalling pathway as well as degranulation. Nonetheless, the limitation of this study is that the NF-κB activity was not measured in mast cells because of low transfection efficiency.

In conclusion, we provide evidence that CRT could be developed as an anti-AD drug because it targets Lyn/Syk kinases which are the most upstream signalling molecules for mast cell degranulation and the production of inflammatory cytokines (Fig. 6C). Further studies examining whether CRT can directly inhibit autophosphorylations of Lyn/Syk kinases and suppress the recruitment of Lyn/Syk kinases to ITAM of FcεRI will be more valuable for therapeutic drug development using CRT.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Research Foundation of Korea grant funded by the Korean government (grant nos. NRF-2016R1A2B2011683, 2016R1A5A1011974, NRF-2015M3A9B6027818 and NRF-2016R1A6A3A11931083).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
SB and SH designed the study, performed the experiments, interpreted the data and were major contributors in writing the manuscript. SL setup the degranulation assay using the RBL-2H3 cell line. ALJ interpreted the results. HIK, JYP and AB performed the RT-PCR and western blot analysis. J-SL setup of the DNCB-induced AD mouse model. M-SL contributed to the preliminary screening of 133 natural compounds. YY conceived the project and interpreted the data. All authors read and approved the final manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate

The present study was approved by the Institutional Animal Care and Use Committee of Sookmyung Women’s University (approval no. SMWU-IACUC-1611-035).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References